Vantage logo

Wrong to try?

Will US right-to-try legislation be a means of giving hope to terminally ill patients, or drug another way for drug regulatory standards to fall?

Vantage logo

Will the real FDA please stand up

The FDA's shifting stance on the efficacy of PD-(L)1 drugs in first-line urothelial bladder cancer does little for those worried about the agency loosing its teeth.